The GLP-1 Fitness Paradox

The scale is moving. The person may be moving less.

Two major fitness stories in 2026 appear to point in opposite directions.

The American College of Sports Medicine ranked Exercise for Weight Management as the third-largest fitness trend of 2026—its highest position in the history of the survey. ACSM specifically identified the growing use of GLP-1 receptor agonist medications as part of the reason exercise professionals are paying greater attention to weight-management programming.

Then researchers presented a more troubling finding at ENDO 2026: adults taking GLP-1 medications did not become more active as they lost weight. On average, they moved less.

That creates the central fitness challenge of the GLP-1 era.

Medication may help reduce body weight, but weight loss does not automatically create strength, improve movement capacity or establish an active lifestyle. In fact, without a deliberate exercise strategy, a person may become lighter while also becoming less physically active.

Losing pounds, not gaining steps

The ENDO 2026 study used electronic health records and Fitbit data from the National Institutes of Health’s All of Us Research Program. Researchers identified 1,950 adults with obesity who had started a GLP-1 receptor agonist, including semaglutide, tirzepatide, liraglutide or dulaglutide. Of those participants, 753 had sufficient activity-tracker data for analysis.

The average participant was approximately 53 years old, and nearly 79 percent of the group was female. Researchers compared daily steps and moderate-to-vigorous physical activity before and after treatment began.

After participants started a GLP-1 medication:

• Average daily steps fell from 5,047 to 4,487.
• Moderate-to-vigorous activity fell from 27.9 to 22.2 minutes per day.
• Men experienced larger declines than women.
• Participants with joint or muscle pain experienced greater reductions in daily steps than those without those conditions.

That represents roughly an 11 percent decline in steps and a 20 percent decline in moderate-to-vigorous activity.

The study does not prove that GLP-1 medication directly caused the reduction. It was a retrospective, before-and-after analysis rather than a randomized trial, and only 38.6 percent of the identified patients had enough Fitbit data to be included. There was also no matched control group showing what would have happened without treatment.

Those limitations matter.

But so does the behavioral pattern captured by the devices. The study challenges the assumption that losing weight naturally causes people to move more. A smaller body may make movement physically easier, but that does not mean exercise habits, confidence, strength or tolerance for activity will develop on their own.

Weight loss can create an opportunity for movement. It does not create the movement itself.

The scale does not measure physical capacity

Body weight is one measurement. It is not a complete description of health or function.

A scale cannot tell whether someone can climb stairs comfortably, get up from the floor, carry groceries, maintain balance, recover from a stumble or preserve enough strength to remain independent later in life.

It also cannot distinguish between fat mass and lean tissue.

Some loss of lean mass commonly occurs during significant weight loss, regardless of the method used. In an exploratory body-composition analysis from the STEP 1 semaglutide trial, participants receiving semaglutide lost substantially more fat mass but also experienced a reduction in total lean body mass. At the same time, lean mass increased as a percentage of their lower total body weight because fat mass declined more sharply.

That distinction is important. Lean mass is not identical to skeletal muscle, and a reduction in measured lean mass does not automatically mean an equivalent loss of functional muscle tissue. Hydration, organ tissue and other fat-free components can affect the measurement.

The practical concern is not that every person taking a GLP-1 medication will experience severe muscle loss. The concern is that rapid weight loss, lower food intake and declining activity can create conditions in which strength and physical capacity are not adequately protected.

The answer is not panic. It is purposeful training.

Exercise is not a backup plan for medication

For years, exercise was often marketed primarily as a way to burn calories. That framing was always incomplete, and GLP-1 medications have made its limitations more obvious.

When medication produces a significant calorie deficit, exercise does not need to compete with the prescription as the primary driver of weight loss. Its more valuable role becomes clearer:

Exercise helps preserve what the person wants to keep.

That includes strength, mobility, work capacity, balance, bone-loading activity, movement confidence and the ability to perform everyday tasks.

This is why ACSM’s 2026 trends report says structured exercise remains essential during weight management. The organization specifically points to lean mass, metabolic health and physical function as outcomes that medication alone does not consistently produce. Traditional strength training also remained one of ACSM’s top ten trends, even though fewer than 30 percent of American adults meet recommended muscle-strengthening guidelines.

Clinical research also suggests that medication and exercise should not be treated as competing strategies. In a randomized trial involving adults with obesity, combining structured exercise with liraglutide improved healthy weight-loss maintenance more than either strategy alone. A follow-up analysis found that one year after treatment ended, the group that had combined exercise with liraglutide retained better body-weight and body-fat outcomes than the group that had used liraglutide without the exercise program.

The medication helped create weight loss. Exercise helped build a more durable physical system around it.

The fitness plan has to begin where the user is

Telling people to “exercise more” is not enough.

The ENDO findings suggest that many GLP-1 users may need a program designed specifically to interrupt declining activity. This is especially important for people already dealing with joint pain, low confidence, fatigue, deconditioning or a long absence from structured exercise.

The answer is not immediately assigning punishing workouts to compensate for the medication. A program should make movement achievable enough to repeat and progressive enough to produce adaptation.

That generally means establishing a manageable baseline of daily movement, introducing resistance training at an appropriate starting level and gradually increasing the demands placed on the body. Exercises may need to be modified around pain, balance limitations, equipment access and current ability.

Progress should also be measured beyond body weight.

Useful indicators can include improvements in exercise technique, repetitions completed, resistance used, walking tolerance, recovery between efforts, balance, movement range and confidence performing everyday tasks. Body-composition assessments may provide additional information when they are performed and interpreted appropriately, but even those numbers should be considered alongside actual physical performance.

The objective is not simply to make the body smaller.

It is to make the person more capable within that body.

Medical treatment and fitness coaching have different jobs

GLP-1 medications are medical treatments. Decisions about prescriptions, dosing, side effects, nutrition concerns and medical monitoring belong with qualified healthcare professionals.

A personal trainer does not replace that care.

The trainer’s role is to translate the need for physical activity into a safe, structured and progressive exercise process. That may include assessing current movement ability, teaching resistance exercises, adapting sessions to readiness, tracking functional progress and helping the client build consistency.

That division of responsibility matters. People do not need fitness professionals pretending to practice medicine, and they do not need exercise treated as an optional footnote to medical weight management.

They need both sides working within their appropriate scope.

A new definition of a successful outcome

The arrival of effective obesity medications has not made fitness less important. It has exposed why fitness was important all along.

Exercise was never valuable only because it helped change the number on a scale. It was valuable because it changed what a person could do.

The ENDO 2026 findings should therefore be treated as an early warning. Weight loss may be occurring while physical activity quietly declines. Unless that decline is addressed deliberately, a person may reach a lower weight without building the strength, movement habits or physical resilience needed to sustain a more active life.

The opportunity created by GLP-1 treatment is substantial. But the medication and the training have different assignments.

The medication may help change body weight.

Training helps determine what the weight loss leaves behind.